Log in

2591 Guangzhou Innogen Pharmaceutical Group Co Ltd HKEX · China

Guangzhou Innogen Pharmaceutical Group Co (2591) news

Guangzhou Innogen Pharmaceutical Group Co Ltd is a public biotech or pharmaceutical company listed on HKEX under the ticker 2591, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Guangzhou Innogen Pharmaceutical Group Co news

We have not published a story on Guangzhou Innogen Pharmaceutical Group Co yet. When there is news, it will appear here.

Questions about Guangzhou Innogen Pharmaceutical Group Co

What is the ticker symbol of Guangzhou Innogen Pharmaceutical Group Co?

Guangzhou Innogen Pharmaceutical Group Co Ltd trades under the ticker 2591 on HKEX.

Where is Guangzhou Innogen Pharmaceutical Group Co listed?

Guangzhou Innogen Pharmaceutical Group Co Ltd is listed on HKEX.

Which country or territory is Guangzhou Innogen Pharmaceutical Group Co listed under?

Our directory records Guangzhou Innogen Pharmaceutical Group Co Ltd under China.

What does Guangzhou Innogen Pharmaceutical Group Co do?

Our directory classifies Guangzhou Innogen Pharmaceutical Group Co Ltd as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Guangzhou Innogen Pharmaceutical Group Co?

The ISIN recorded for Guangzhou Innogen Pharmaceutical Group Co Ltd is CNE1000071Q7.

Does aibio.space cover Guangzhou Innogen Pharmaceutical Group Co?

aibio.space lists Guangzhou Innogen Pharmaceutical Group Co Ltd among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Guangzhou Innogen Pharmaceutical Group Co?

Companies in our directory listed in the same country and business area as Guangzhou Innogen Pharmaceutical Group Co: Wuhan YZY Biopharma Co., Chengdu Huasun Technology Group Inc., Hygeia Healthcare Holdings Co., Xiangxue Pharmaceutical Co., Zhejiang Benli Technology Co., China National Medicines Corporation.

Investor discussion: Guangzhou Innogen Pharmaceutical Group Co

Members talk about Guangzhou Innogen Pharmaceutical Group Co (2591). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Guangzhou Innogen Pharmaceutical Group Co, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: CIRCULAR FOR THE 2025 ANNUAL GENERAL MEETING. Source

  2. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS. Source

  3. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS. Source

  4. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS. Source

  5. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS; AND NON-COMPLIANCE OF LISTING RULES. Source

  6. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of Guangzhou Innogen Pharmaceutical Group Co's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF SENIOR MANAGEMENT

  2. HKEXnews

    (1) RESIGNATION OF DIRECTORS; AND (2) CHANGE IN COMPOSITION OF STRATEGY COMMITTEE

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - VOLUNTARY LOCK-UP UNDERTAKING BY THE FOUNDER OF THE GROUP AND CERTAIN SENIOR MANAGEMENT

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INTENTION TO CONDUCT ON-MARKET H SHARE REPURCHASE

  5. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - OBTAINMENT OF PIC/S GMP CERTIFICATES FOR TWO CONTRACT MANUFACTURING SITES FOR EFSUBAGLUTIDE ALFA INJECTION

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON CLINICAL TRIAL OF EFSUBAGLUTIDE ALFA FOR THE TREATMENT OF OBESITY FOR ADOLESCENTS

  8. HKEXnews

    TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

  9. HKEXnews

    Articles of Association

  10. HKEXnews

    (I) POLL RESULTS OF THE ANNUAL GENERAL MEETING AND (II) ABOLITION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON CLINICAL TRIAL OF EFSUBAGLUTIDE ALFA FOR THE TREATMENT OF OBESITY FOR ADOLESCENTS

  12. HKEXnews

    Share Award Scheme

  13. HKEXnews

    NOTICE OF THE ANNUAL GENERAL MEETING

  14. HKEXnews

    CIRCULAR FOR THE 2025 ANNUAL GENERAL MEETING

  15. HKEXnews

    (1) PROPOSED ADOPTION OF SHARE AWARD SCHEME; AND (2) PROPOSED AUTHORIZATION TO THE BOARD AND/OR ITS AUTHORIZED PERSONS TO DEAL WITH MATTERS PERTAINING TO SHARE AWARD SCHEME

  16. HKEXnews

    (1) PROPOSED RE-ELECTION OF DIRECTORS; (2) ABOLITION OF THE SUPERVISORY COMMITTEE AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND (3) PROPOSED AMENDMENTS TO THE RULES OF PROCEDURES FOR THE GENERAL MEETING AND THE RULES OF PROCEDURES FOR THE BOARD OF DIRECTORS

  17. HKEXnews

    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

  18. HKEXnews

    CHANGE OF JOINT COMPANY SECRETARY; AGENT FOR SERVICE OF PROCESS AND AUTHORISED REPRESENTATIVE; AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

  19. HKEXnews

    INSIDE INFORMATION PROFIT WARNING

  20. HKEXnews

    INSIDE INFORMATION PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2591 on TradingView.

Listing details

Guangzhou Innogen Pharmaceutical Group Co Ltd is a public biotech or pharmaceutical company listed on HKEX under the ticker 2591, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Guangzhou Innogen Pharmaceutical Group Co Ltd
Ticker
2591
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
CNE1000071Q7
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.